Ongoing access to experimental ITP drug for japanese patients
NCT ID NCT07216079
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 22 times
Summary
This study offers continued treatment with the oral drug rilzabrutinib to adults with chronic immune thrombocytopenia (ITP) who have already completed a long-term extension study in Japan. Only 4 participants who showed meaningful benefit and acceptable safety are eligible. The main goal is to monitor side effects while providing ongoing disease control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number: 1001
Tsuchiura, Ibaraki, 300-0028, Japan
-
Investigational Site Number: 1002
Kanazawa, Ishikawa-ken, 920-8641, Japan
-
Investigational Site Number: 1003
Iruma-gun, Saitama, 350-0495, Japan
Conditions
Explore the condition pages connected to this study.